Second trial drugs in ovarian cancer.
D006585:Altretamine / Q000009:adverse effects / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D003609:Dactinomycin / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008558:Melphalan / Q000009:adverse effects / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D013852:Thiotepa / Q000009:adverse effects / Q000627:therapeutic use
D003609:Dactinomycin; D004317:Doxorubicin; D003520:Cyclophosphamide; D013852:Thiotepa; D008558:Melphalan; D006585:Altretamine; D005472:Fluorouracil